The OncLive Immunotherapy in Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on available and investigational immunotherapies in lung cancer. This page features news articles, interviews in written and video format, and podcasts that focus on updates with checkpoint inhibitors and the ongoing research with this type of treatment in non–small cell lung cancer and small cell lung cancer.
March 25th 2024
Durvalumab/chemoradiation did not significantly improve survival vs chemoradiation alone in patients with unresectable non–small cell lung cancer.